Considering the biocompatibility, safety, and efficiency of UTMD technology, the synergistic therapy of melatonin treatment and RORα/CMBs may be a promising therapeutic pattern against sepsis-induced cardiomyopathy. Here, RORA is linked to cardiomyopathy.